Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 6, 2013, Pages 291-304

  Brown, Jacques P ^a   Boulay, Luc J ^b  

^a LAVAL UNIVERSITY   (Canada)

^b Eli Lilly ^*  (Canada)

Author keywords

Chronic pain management; drug interactions; duloxetine; osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTICOAGULANT AGENT; CIPROFLOXACIN; CODEINE; CORTICOSTEROID; CYTOCHROME P450 1A2; DULOXETINE; ENDOXIFEN; FLUOXETINE; FLUVOXAMINE; HYALURONIC ACID; HYPERICUM PERFORATUM EXTRACT; METHADONE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PAROXETINE; PENTAZOCINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TAPENTADOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; WARFARIN;

ANXIETY; ARTHRALGIA; BECK DEPRESSION INVENTORY; CHRONIC PAIN; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; COUGHING; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEART PALPITATION; HEPATITIS; HUMAN; HYPERHIDROSIS; HYPERTRANSAMINASEMIA; INCIDENCE; INSOMNIA; JAUNDICE; KNEE OSTEOARTHRITIS; KNEE PAIN; LIVER FAILURE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SCORING SYSTEM; SOMNOLENCE; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 84888242735     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13508508     Document Type: Review

References (67)

1. Altman R. Asch E. Bloch D. Bole G. Borenstein D. Brandt K. et al. (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29: 1039–1049.
2. American Academy of Orthopaedic Surgeons (2008) American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont, IL: American Academy of Orthopaedic.
3. Apkarian A. Bushnell M. Treede R. Zubieta J. (2005) Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 9: 463–484.
4. Arnold L. Lu Y. Crofford L. Wohlreich M. Detke M. Iyengar S. et al. (2004) HMBO - A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50: 2974–2984.
5. Arnold L. Rosen A. Pritchett Y. D'Souza D. Goldstein D. Iyengar S. et al. (2005) HMCA - A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119: 5–15.
6. Beck A. Epstein N. Brown G. Steer R. (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893–897.
7. Bellamy N. Buchanan W. Goldsmith C. Campbell J. Stitt L. (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15: 1833–1840.
8. Benn S. Woolf C. (2004) Adult neuron survival strategies–slamming on the brakes. Nat Rev Neurosci 5: 686–700.
9. Bolay H. Moskowitz M. (2002) Mechanisms of pain modulation in chronic syndromes. Neurology 59: S2–S7.
10. bou-Raya S. bou-Raya A. Helmii M. (2012) Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing 41: 646–652.
11. Brunton S. Wang F. Edwards S. Crucitti A. Ossanna M. Walker D. et al. (2010) Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 33: 393–407.
12. Chappell A. Bradley L. Wiltse C. Detke M. D'Souza D. Spaeth M. (2009 a) A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 1: 91–102.
13. Chappell A. Desaiah D. Liu-Seifert H. Zhang S. Skljarevski V. Belenkov Y. et al. (2011) A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 11: 33–41.
14. Chappell A. Littlejohn G. Kajdasz D. Scheinberg M. D'Souza D. Moldofsky H. (2009 b) A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 25: 365–375.
15. Chappell A. Ossanna M. Liu-Seifert H. Iyengar S. Skljarevski V. Li L. et al. (2009 c) Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 146: 253–260.
16. Chen A. Gupte C. Akhtar K. Smith P. Cobb J. (2012) The global economic cost of osteoarthritis: how the UK compares. Arthritis 2012:698709.
17. Cleeland C. Ryan K. (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129–138.
18. Creamer P. (2000) Osteoarthritis pain and its treatment. Curr Opin Rheumatol 12: 450–455.
19. Cubukcu D. Sarsan A. Alkan H. (2012) Relationships between pain, function and radiographic findings in osteoarthritis of the knee: a cross-sectional study. Arthritis 2012: 984060.
20. de Santana J. Sluka K. (2008) Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain. Curr Pain Headache Rep 12: 338–343.
21. Dworkin R. Turk D. Farrar J. Haythornthwaite J. Jensen M. Katz N. et al. (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113: 9–19.
22. Dworkin R. Turk D. McDermott M. Peirce-Sandner S. Burke L. Cowan P. et al. (2009) Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 146: 238–244.
23. Dworkin R. Turk D. Peirce-Sandner S. Baron R. Bellamy N. Burke L. et al. (2010) Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 149: 177–193.
24. Dworkin R. Turk D. Wyrwich K. Beaton D. Cleeland C. Farrar J. et al. (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9: 105–121.
25. Eli Lilly Canada Inc. (2012) Product Monograph: Cymbalta duloxetine.
26. Felson D. Naimark A. Anderson J. Kazis L. Castelli W. Meenan R. (1987) The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 30: 914–918.
27. Fields H. Heinricher M. Mason P. (1991) Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 14: 219–245.
28. Finan P. Buenaver L. Bounds S. Hussain S. Park R. Haque U. et al. (2013) Discordance between pain and radiographic severity in knee osteoarthritis: findings from quantitative sensory testing of central sensitization. Arthritis Rheum 65: 363–372.
29. Frakes E. Risser R. Ball T. Hochberg M. Wohlreich M. (2011) Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 27: 2361–2372.
30. Goldstein D. Lu Y. Detke M. Lee T. Iyengar S. (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116: 109–118.
31. Guy W. (1976) ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education, and Welfare Publication (ADM). National Institute of Mental Health.
32. Hochberg M. Altman R. April K. Benkhalti M. Guyatt G. McGowan J. et al. (2012 a) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 64: 465–474.
33. Hochberg M. Wohlreich M. Gaynor P. Hanna S. Risser R. (2012 b) Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 39: 352–358.
34. Iannone F. Lapadula G. (2003) The pathophysiology of osteoarthritis. Aging Clin Exp Res 15: 364–372.
35. Iyengar S. Webster A. Hemrick-Luecke S. Xu J. Simmons R. (2004) Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311: 576–584.
36. Jinks C. Jordan K. Croft P. (2002) Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 100: 55–64.
37. Jordan K. Arden N. Doherty M. Bannwarth B. Bijlsma J. Dieppe P. et al. (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62: 1145–1155.
38. Kind P. (1996) The EuroQoL instrument: an index of health-related quality of life. In: Ed. Spilker B. (ed.), Quality of Life and Pharmaco Economics in Clinical Trials. Philadelphia, PA: Lippincott-Raven Publishers, pp. 191–201.
39. Marchand S. (2012) The Phenomenon of Pain. Seattle, WA: IASP Press.
40. Martel-Pelletier J. Wildi L. Pelletier J. (2012) Future therapeutics for osteoarthritis. Bone 51: 297–311.
41. McAlindon T. Cooper C. Kirwan J. Dieppe P. (1993) Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis 52: 258–262.
42. Mease P. Hanna S. Frakes E. Altman R. (2011) Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. J Rheumatol 38: 1546–1551.
43. Melzack R. (1999) From the gate to the neuromatrix. Pain Suppl 6: S121–S126.
44. Melzack R. Wall P. (1965) Pain mechanisms: a new theory. Science 150: 971–979.
45. Micca J. Ruff D. Ahl J. Wohlreich M. (2013) Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials. BMC Musculoskelet Disord 14: 137.
46. Pham T. van der Heijde D. Altman R. Anderson J. Bellamy N. Hochberg M. et al. (2004) OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 12: 389–399.
47. Phillips K. Clauw D. (2013) Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum 65: 291–302.
48. Raskin J. Pritchett Y. Wang F. D'Souza D. Waninger A. Iyengar S. et al. (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6: 346–356.
49. Richardson B. (1990) Serotonin and nociception. Ann N Y Acad Sci 600: 511–519.
50. Russell I. Mease P. Smith T. Kajdasz D. Wohlreich M. Detke M. et al. (2008) HMCJ - Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136: 432–444.
51. Sarzi-Puttini P. Cimmino M. Scarpa R. Caporali R. Parazzini F. Zaninelli A. et al. (2005) Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 35: 1–10.
52. Scholz J. Woolf C. (2002) Can we conquer pain? Nat Neurosci 5(Suppl.): 1062–1067.
53. Schweinhardt P. Bushnell M. (2010) Pain imaging in health and disease - how far have we come? J Clin Invest 120: 3788–3797.
54. Skljarevski V. Desaiah D. Liu-Seifert H. Zhang Q. Chappell A. Detke M. et al. (2010 a) Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976) 35: E578–E585.
55. Skljarevski V. Ossanna M. Liu-Seifert H. Zhang Q. Chappell A. Iyengar S. et al. (2009) A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 16: 1041–1048.
56. Skljarevski V. Zhang S. Desaiah D. Alaka K. Palacios S. Miazgowski T. et al. (2010 b) Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 11: 1282–1290.
57. Sofat N. Ejindu V. Kiely P. (2011) What makes osteoarthritis painful? The evidence for local and central pain processing. Rheumatology (Oxford) 50: 2157–2165.
58. Staud R. (2011) Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep 13: 513–520.
59. Turk D. Dworkin R. Allen R. Bellamy N. Brandenburg N. Carr D. et al. (2003) Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106: 337–345.
60. Ware J. Snow K. Kosinski M. Gandek B. (1993) SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center.
61. Wernicke J. Pritchett Y. D'Souza D. Waninger A. Tran P. Iyengar S. et al. (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67: 1411–1420.
62. Whitmyer V. Dunner D. Kornstein S. Meyers A. Mallinckrodt C. Wohlreich M. et al. (2007) A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 68: 1921–1930.
63. Woolf A. Pfleger B. (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81: 646–656.
64. Woolf C. (2004) Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140: 441–451.
65. World Health Organization (2002) World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva: WHO.
66. Zhang W. Doherty M. Peat G. Bierma-Zeinstra M. Arden N. Bresnihan B. et al. (2010) EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 69: 483–489.
67. Zhang W. Moskowitz R. Nuki G. Abramson S. Altman R. Arden N. et al. (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16: 137–162.